These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17011787)

  • 21. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
    Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
    Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.
    Graham ML; Asselin BL; Herndon JE; Casey JR; Chaffee S; Ciocci GH; Daeschner CW; Davis AR; Gold S; Halperin EC; Laughlin MJ; Martin PL; Olson JF; Kurtzberg J
    Bone Marrow Transplant; 1998 May; 21(9):879-85. PubMed ID: 9613779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asparaginase in acute lymphoblastic leukemia.
    Kawedia JD; Rytting ME
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.
    Müller HJ; Beier R; da Palma JC; Lanvers C; Ahlke E; von Schütz V; Gunkel M; Horn A; Schrappe M; Henze G; Kranz K; Boos J
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):149-54. PubMed ID: 11862429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-asparaginase: a promising chemotherapeutic agent.
    Verma N; Kumar K; Kaur G; Anand S
    Crit Rev Biotechnol; 2007; 27(1):45-62. PubMed ID: 17364689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
    Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
    Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
    Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
    Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in L-asparaginase discovery and its potential as anticancer agent.
    Shrivastava A; Khan AA; Khurshid M; Kalam MA; Jain SK; Singhal PK
    Crit Rev Oncol Hematol; 2016 Apr; 100():1-10. PubMed ID: 25630663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEG-linked asparaginase marketed.
    Am J Hosp Pharm; 1994 Jun; 51(11):1382. PubMed ID: 7942872
    [No Abstract]   [Full Text] [Related]  

  • 36. Pegaspargase.
    Alfieri DR
    Pediatr Nurs; 1995; 21(5):471-4, 490. PubMed ID: 8684851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Pinheiro JP; Lanvers C; Würthwein G; Boos J
    Blood; 2002 Sep; 100(5):1923-4; author reply 1924-5. PubMed ID: 12211194
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
    Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
    Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.